New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 8, 2012
12:00 EDTGRFSGrifols: First patient enrolled in Phase 2 trial of Alpha-1 HC
Grifols announced that the first patient has been enrolled and dosed in a phase II study evaluating the safety and tolerability of Alpha-1 HC aerosol in patients with cystic fibrosis. Cystic fibrosis is an inherited disease that causes progressive decline in lung function, including acute episodes of worsening respiratory symptoms and potentially fatal lung infections. The multicenter trial will investigate two doses of Alpha-1 HC aerosol, an inhaled formulation of Grifols' alpha1-proteinase inhibitor (human). Investigators will measure adverse events and other end points during the three-week study period. The randomized, double-blind, placebo-controlled trial will enroll 30 patients at six sites across the U.S.
News For GRFS From The Last 14 Days
Check below for free stories on GRFS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
08:34 EDTGRFSGrifols recent pullback a buying opportunity, says Morgan Stanley at Morgan Stanley
Morgan Stanley views the recent pullback in Grifols as a buying opportunity. The firm said Q2 results were disappointing but there is no change to fundamentals and expects 2H improvement. Shares are Overweight rated with a $44 price target, down from $48.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use